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Tumor Necrosis Factor-a and Host Resistance to the
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George S. Deepe Jr1
Tumor necrosis factor-alpha (TNF-a) is a multifunctional cytokine that is critically important in host defenses to a
number of pathogenic microbes. Among those, this cytokine is necessary for control of infection with the
pathogenic fungus, Histoplasma capsulatum. Antagonism of endogenous cytokine is associated with an
enhanced susceptibility to histoplasmosis in both mice and humans. The mechanisms by which TNF-a
modulates the protective immune response will be discussed.
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INTRODUCTION
Tumor necrosis factor alpha (TNF)-a is a multifunctional
cytokine generated by a wide range of cell populations. One
of its major functions is related to host defenses. It is an
important stimulus in (1) the flux of inflammatory cells, (2) the
formation of granulomas, (3) the generation of nitric oxide,
and (4) the regulation of other cytokines and chemokines
(Beutler and Cerami, 1989; Feldmann and Maini, 2001).
TNF-a mediates its functions through engagement of two
receptors, TNF receptor (TNFR)1 and 2. The receptors are
different in protein composition and binding to each receptor
produces different biochemical outcomes (Aggarwal, 2003).
In several models of infectious diseases, the presence of
endogenous TNF-a is crucial for effective host resistance
mechanisms. Neutralization of this cytokine exacerbates
infection with Mycobacterium tuberculosis, Listeria mono-
cytogenes, Leishmania major, and Toxoplasma gondii (Flynn
et al., 1995; Deckert-Schluter et al., 1998; White et al., 2000;
Wilhelm et al., 2001; Botha and Ryffel, 2003; Schluter et al.,
2003; Serbina et al., 2003). Control of infections with
pathogenic fungi also is dependent on the presence of
TNF-a. Experimental candidiasis, aspergillosis, blastomycosis,
and histoplasmosis require this cytokine for control of infection
or for vaccine-induced immunity (Smith et al., 1990; Wu-
Hsieh et al., 1992; Steinshamn et al., 1996; Marino et al.,
1997; Allendoerfer and Deepe, 1998, 2000; Zhou et al., 1998;
Mehrad et al., 1999; Finkel-Jimenez et al., 2002).
Histoplasma capsulatum is a pathogenic fungus that is
found in most areas of the world and is endemic to the
midwestern and southeastern United States. Most infections
are either clinically unapparent or manifest with a flu-like
illness that resolves without treatment. Microconidia or
hyphal fragments are inhaled from the soil, deposit within
the terminal bronchioles and alveoli of lungs, and convert in
the pathogenic yeast phase. These fungal elements grow within
macrophages until cellular immunity has been activated.
Like M. tuberculosis, H. capsulatum can establish a latent
state within the confines of granulomas. The organisms
presumably remain dormant until the host response becomes
impaired either by immunosuppressive agents or by
co-morbid conditions such as acquired immunodeficiency
syndrome. Although reactivation histoplasmosis has been
documented, it is often difficult to distinguish reactivation
from re-infection in endemic areas. In the last few years, one
of the major risk factors for the appearance of progressive
histoplasmosis has been the use of antagonists of TNF-a in
humans (Lee et al., 2002; Wood et al., 2003). Thus,
histoplasmosis in patients receiving mAb to this cytokine
has been the subject of numerous reports. In the following
paragraphs, a review of the immunoregulatory properties of
TNF-a as they pertain to H. capsulatum will be discussed.
EFFECT OF NEUTRALIZATION OF TNF-a IN PRIMARY
INFECTION
After infection of mice with H. capsulatum yeast cells, there
is a prompt and brisk induction of TNF-a generation (Smith
et al., 1990; Wu-Hsieh et al., 1992). An increase in a
cytokine does not necessarily indicate that the cytokine is
involved in host defenses. Several groups used either
polyclonal or mAb to TNF-a to neutralize endogenous
cytokine. In both primary and secondary infections, neutra-
lization of this cytokine leads to a progressive infection and
subsequent death of the animals (Smith et al., 1990;
Wu-Hsieh et al., 1992; Allendoerfer and Deepe, 1998; Zhou
et al., 1998). Thus, TNF-a serves as a bridge from innate to
adaptive immunity. Moreover, once adaptive immunity has
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been imprinted, TNF-a is required for its maintenance in the
face of a re-challenge with H. capsulatum.
All of the preceding studies studied the effect of TNF-a
neutralization at the time of infection. This approach does not
address if this cytokine is necessary after infection has been
established. In primary infection, neutralization of this
cytokine as late as day 5 after infection with a non-lethal
inoculum produced a high rate of mortality in mice.
Neutralizing TNF-a on day 7 of infection when cellular
immunity is activated dampened the host response transiently
but did not lead to an uncontrolled infection. (Deepe and
Gibbons, 2006).
The defects in immunity associated with the absence of
this cytokine remain to be clarified. Two defects have been
uncovered in primary infection. In mice given neutrali-
zing mAb to TNF-a, there is a sharp reduction in the
production of nitric oxide. This nitrogen intermediate has
been shown to be necessary for the expression of protective
immunity in primary but not secondary infection (Lane
et al., 1994; Zhou et al., 1995). Interestingly, neutralization
of TNF-a did not alter production of IFN-g although others
have reported that production of these two cytokines may be
interdependent (Allendoerfer and Deepe, 1998). A second
defect is that T cells from mice infected with H. capsulatum
and given mAb cannot transfer protective immunity into
mice lacking ab T cells whereas T cells from infected
animals given rat IgG can. Thus, the absence or deficiency of
TNF-a does alter the protective effect by T cells. The
dysfunction of the T cells from mice lacking TNF-a is not
associated with fewer IFN-g T cells or alterations in the
ability of these cells to traffic properly (Deepe and Gibbons,
2006).
TNF-a is proinflammatory cytokine. Thus, one would
expect that neutralization would diminish the number of
inflammatory cells within the lungs of mice infected with
H. capsulatum. However, recovery of cells from the lungs of
mice infected with H. capsulatum and given mAb to TNF-a
demonstrates no major alterations; in fact, recovery of cells is
increased (Allendoerfer and Deepe, 1998).
EFFECT OF TNF-a NEUTRALIZATION IN SECONDARY
HISTOPLASMOSIS
Neutralization of TNF-a in mice with secondary histoplas-
mosis produces a different set of immunological disturbances.
There is upregulation in the production of IL-4 and -10, two
cytokines that are known to diminish protective immunity to
this fungus (Allendoerfer and Deepe, 1998). Neutralization of
both, but not each alone, promotes the restoration of
protective immunity. T cells from infected mice given mAb
to TNF-a are incapable of transferring protection as was the
case with T cells from anti-TNF-a-treated mice with primary
histoplamosis. Treatment of mice with anti-TNF-a antibody
on the day of infection or day 3 post-infection abolished
protective immunity. When the antibody was given on day 5
post-infection, there was an impact on fungal burden but not
on the eventual survival of mice (Deepe and Gibbons, 2006).
The finding that TNF-a neutralization in both primary and
secondary histoplasmosis induces T cells that cannot transfer
protection requires an explanation. One possibility is that a
deficiency of this cytokine leads to defective T cells.
However, as assessed by CD69 they were capable of being
activated. There was a significant decrease in the number of
memory T cells in mice given mAb to TNF-a. These cells may
be the effector cells that deliver the signals that lead to
protection. However, their ability to produce IFN-g was not
diminished. Another possibility is that the absence of TNF-a is
associated with the generation of regulatory T cells. Support
for this argument comes from two studies. In non-obese
diabetic mice, neutralization of endogenous TNF-a increases
the number and the activity of regulatory T cells. This cell
population is known to dampen or suppress cellular
immunity. Administration of recombinant cytokine leads to
a decrement in number and function of these cells (Wu et al.,
2002). In a separate study, treatment of rheumatoid arthritis
patients with infliximab, the mAb to TNF-a for humans, is
associated with an increase in the number and functional
properties of regulatory T cells (Ehrenstein et al., 2004). Thus,
the salutary effect of infliximab may be explained in part on
the generation of this cell population, which inhibits
inflammation. Although dampening cellular immunity may
be beneficial for inflammatory diseases, it may enhance
susceptibility to pathogenic microbes, especially those that
are intracellular. In this regard, we are currently exploring
whether treatment with mAb to TNF-a in mice is accom-
panied by the emergence of regulatory T cells in the lungs of
H. capsulatum-infected mice.
TNFR KNOCKOUT MICE
Signaling of TNF-a occurs through two receptors, and the
downstream effects of engaging one or another may overlap,
although distinct functions can be ascribed to binding one or
the other receptor. Mice lacking either TNFR1 or TNFR2
are susceptible to primary infection with 2106 yeasts of
H. capsulatum but mice lacking TNFR2 are more resistant to
smaller inocula. The major immunological defect in TNFR1/
mice is a paucity of inflammatory cells within lungs. One
possibility to explain these findings is that the absence of
TNFR1 alters chemokine generation. In TNFR2/ mice, we
found a profound deficiency in IFN-g, and treatment of the
latter with recombinant cytokine restored protective immu-
nity. In neither TNFR1 nor TNFR2 mice did we find a
deficiency of nitric oxide (Allendoerfer and Deepe, 2000).
These findings differed from those found in mice that
received anti-TNF-a mAb. Although the central disturbance
of each of these experiments was TNF-a and its signaling, the
results highlight the sharp biological disparities among
antibody neutralization and failure to signal through one of
the receptors.
In secondary histoplasmosis, antagonizing TNFR1 engage-
ment using a blocking antibody alters handling of
H. capsulatum in secondary infection. The reason for using
a blocking antibody rather than TNFR1/ mice is that the
latter do not survive a low dose of the fungus even with
potent antifungal treatment (Allendoerfer and Deepe, 2000)
Thus, we had to resort to using a blocking antibody rather
than the knockout mice.
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HISTOPLASMOSIS IN HUMANS RECEIVING TNF-a
ANTAGONISTS
Post-marketing surveillance for the TNF-a antagonists has
strongly suggested that disseminated histoplasmosis is a risk
factor in patients receiving these agents although an absolute
risk value cannot be assigned. The mechanisms that lead to
the emergence or the re-emergence of the fungus have only
recently begun to be investigated. In vitro, infliximab
modestly enhances intracellular growth of yeast cells, but
depresses proliferation of peripheral blood lymphocytes from
healthy subjects to H. capsulatum only when alveolar
macrophages were used as antigen-presenting cells (Wood
et al., 2003). If macrophages or dendritic cells are used as
antigen-presenting cells then the effect is not seen (Hage
et al., 2005). These results have been interpreted to suggest
that the effect of infliximab is compartmentalized to the
alveolar macrophage. This mAb also suppresses production
of IFN-g by either monocytes or alveolar macrophages from
healthy subjects.
One of the difficulties for clinicians is determining who
will develop histoplasmosis in those given TNF-a antagonists.
At present, no skin test reagent is commercially available to
screen patients for the presence of exposure to H. capsula-
tum. Chest X-rays may demonstrate calcified lesions con-
sistent with granulomas, but these may be a result of either
tuberculosis or histoplasmosis. The risk of developing
histoplasmosis in patients with X-rays consistent with
granulomas has not been determined. Thus, the presence
on chest X-ray of the calcified lesions should alert physicians
to the possibility that reactivation histoplasmosis may occur.
The onset of a new intercurrent illness suggestive of this
fungal infection should prompt immediate evaluation and if
necessary, treatment.
SUMMARY
The accumulated evidence both in experimental animals and
in humans indicates that TNF-a is a critical factor in host
resistance to H. capsulatum. The focus of the current work in
mice has been to uncover the mechanisms by which this
cytokine exerts its functional properties. Less has been done
in humans because the number of cases, while increased, is
not large. As it is possible that the response in humans may
differ from that in mice, studies aimed at addressing these
issues in humans is imperative.
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